PMID- 30537634
OWN - NLM
STAT- MEDLINE
DCOM- 20190503
LR  - 20190503
IS  - 1878-1705 (Electronic)
IS  - 1567-5769 (Linking)
VI  - 67
DP  - 2019 Feb
TI  - Pseudoginsenoside-F11 attenuates cognitive impairment by ameliorating oxidative 
      stress and neuroinflammation in d‑galactose-treated mice.
PG  - 78-86
LID - S1567-5769(18)30571-X [pii]
LID - 10.1016/j.intimp.2018.11.026 [doi]
AB  - Oxidative stress and neuroinflammation are thought to be the two key early events 
      during the process of mild cognitive impairment (MCI). Therefore, effective 
      regulation of oxidative stress and neuroinflammation is an important aspect of 
      preventing and improving MCI. We previously found that pseudoginsenoside-F11 
      (PF11), an ocotillol-type saponin, markedly reduced cognitive impairment in 
      APP/PS1 mice and oAbeta(1-42)-injected mice. In the present study, we further 
      evaluate the effect of PF11 on learning and memory dysfunction in d‑galactose 
      (d‑gal)-treated mice model of MCI. C57BL/6 mice received daily subcutaneous 
      injections of d‑gal (100 mg/kg) and oral administration of PF11 (2, 4, 8, 
      16 mg/kg) for 9 weeks. We observed that PF11 significantly alleviated 
      d‑gal-induced cognitive impairment, attenuated the loss of neuron and the 
      over-activation of microglia in hippocampus of d‑gal-treated mice. The elevated 
      levels of nod-like receptor protein 3 (NLRP3) inflammasome in hippocampus of 
      d‑gal-treated mice were reduced by PF11 through reducing the accumulation of 
      advanced glycation endproducts (AGEs) and the expression of the receptor of 
      advanced glycation endproducts (RAGE). Moreover, PF11 significantly decreased 
      H(2)O(2) and malondialdehyde (MDA) levels, improved superoxide dismutase (SOD) 
      activity and increased glutathione (GSH) level in d‑gal-treated mice. Finally, 
      d‑gal treatment reduced the level of nuclear factor erythroid-related factor 2 
      (Nrf2) and glutathione S-transferase (GST) in hippocampus, which could reverse by 
      PF11. Together, our findings indicated that PF11 exerts a protective effect 
      against MCI-like pathological changes.
CI  - Copyright (c) 2018. Published by Elsevier B.V.
FAU - Zhang, Zhen
AU  - Zhang Z
AD  - Department of Pharmacology, Shenyang Pharmaceutical University, Shenyang, PR 
      China.
FAU - Yang, Hanlin
AU  - Yang H
AD  - Department of Pharmacology, Shenyang Pharmaceutical University, Shenyang, PR 
      China.
FAU - Yang, Jingyu
AU  - Yang J
AD  - Department of Pharmacology, Shenyang Pharmaceutical University, Shenyang, PR 
      China.
FAU - Xie, Jun
AU  - Xie J
AD  - Department of Pharmacology, Shenyang Pharmaceutical University, Shenyang, PR 
      China.
FAU - Xu, Jiaoyan
AU  - Xu J
AD  - Department of Pharmacology, Shenyang Pharmaceutical University, Shenyang, PR 
      China.
FAU - Liu, Chen
AU  - Liu C
AD  - Department of Pharmacology, Shenyang Pharmaceutical University, Shenyang, PR 
      China.
FAU - Wu, Chunfu
AU  - Wu C
AD  - Department of Pharmacology, Shenyang Pharmaceutical University, Shenyang, PR 
      China. Electronic address: wucf@syphu.edu.cn.
LA  - eng
PT  - Journal Article
DEP - 20181208
PL  - Netherlands
TA  - Int Immunopharmacol
JT  - International immunopharmacology
JID - 100965259
RN  - 0 (Antioxidants)
RN  - 0 (Ginsenosides)
RN  - 0 (NF-E2-Related Factor 2)
RN  - 0 (Nfe2l2 protein, mouse)
RN  - 0 (pseudoginsenoside F11)
RN  - BBX060AN9V (Hydrogen Peroxide)
RN  - X2RN3Q8DNE (Galactose)
SB  - IM
MH  - Animals
MH  - Antioxidants/*therapeutic use
MH  - Cells, Cultured
MH  - Cognitive Dysfunction/*drug therapy
MH  - Disease Models, Animal
MH  - Galactose/administration & dosage
MH  - Ginsenosides/*therapeutic use
MH  - Hippocampus/*pathology
MH  - Humans
MH  - Hydrogen Peroxide/metabolism
MH  - Male
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Microglia/*drug effects/physiology
MH  - NF-E2-Related Factor 2/metabolism
MH  - Neurogenic Inflammation/*drug therapy
MH  - Neurons/*drug effects/physiology
MH  - Oxidative Stress/drug effects
OTO - NOTNLM
OT  - Mild cognitive impairment
OT  - Neuroinflammation
OT  - Oxidative stress
OT  - Pseudoginsenoside-F11
OT  - d‑Galactose
EDAT- 2018/12/12 06:00
MHDA- 2019/05/06 06:00
CRDT- 2018/12/12 06:00
PHST- 2018/09/06 00:00 [received]
PHST- 2018/10/24 00:00 [revised]
PHST- 2018/11/16 00:00 [accepted]
PHST- 2018/12/12 06:00 [pubmed]
PHST- 2019/05/06 06:00 [medline]
PHST- 2018/12/12 06:00 [entrez]
AID - S1567-5769(18)30571-X [pii]
AID - 10.1016/j.intimp.2018.11.026 [doi]
PST - ppublish
SO  - Int Immunopharmacol. 2019 Feb;67:78-86. doi: 10.1016/j.intimp.2018.11.026. Epub 
      2018 Dec 8.